Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 3 Open Access

Efficacy of High Dose Amoxicillin Therapy in the Eradication of *H.Pylori*

Dr Saranya Punniyakotti[1,*], Dr Nithya Varadarajan[2], Dr Sambasivasam Gopinath[3], Dr Abiramasundari V K[4], Dr Ramaiyan Velmurugan[5]

[1] - Professor, Department of Pharmacy Practice, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences SIMATS, Chennai 602105, India. Email: saro08bpharm@gmail.com, **ORCID ID:** 0000-0003-0802-7999

[2] -Associate Professor, Department of Pharmacology, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences SIMATS, Chennai 602105, India.

[3] -Associate Professor, Department of Pharmacy Practice, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences SIMATS, Chennai 602105, India.

[4] - Associate professor, Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences SIMATS, Chennai 602105, India. ORCID ID: 0000 0001 7362 5106

[5]- Professor, Saveetha College of Pharmacy,Saveetha Institute of Medical and Technical Sciences SIMATS, Chennai 602105, India.

Corresponding Author: Prof. Dr Saranya Punniyakotti, Department of Pharmacy Practice, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences SIMATS, Chennai 602105, India. **Email:**saro08bpharm@gmail.com, **ORCID ID:** 0000-0003-0802-7999

Cite this paper as: Saranya Punniyakotti,Nithya Varadarajan,Sambasivasam Gopinath, Abiramasundari V K, Ramaiyan Velmurugan (2024) Efficacy of High Dose Amoxicillin Therapy in the Eradication of H.Pylori. *Frontiers in Health Informatics, 13* (3), 5751-5754

ABSTRACT

This article provides a comprehensive review of the efficacy of high-dose amoxicillin therapy (HDAT) for the eradication of Helicobacter pylori, with a focus on the variability of outcomes observed across diverse populations. Research indicates that the effectiveness of HDAT may be influenced by regional and genetic factors, highlighting the need for tailored, population-specific treatment strategies. Despite limitations, recent studies report improved eradication rates with HDAT, particularly in regions heavily impacted by antibiotic resistance. However, challenges such as complex treatment regimens, side effects, and patient non-adherence continue to impede global eradication efforts. This article explores the intricate factors influencing H. pylori prevalence and treatment, including the bacterium's role in carcinogenesis and the evolving paradigms in therapeutic approaches. Additionally, advancements in HDAT are discussed, focusing on its pharmacodynamic properties and clinical efficacy. Emphasis is placed on the importance of tailoring therapies to individual patient profiles, advancing personalized medicine. The need for better diagnostic tools, coordinated public health efforts, and innovative therapeutic development is also highlighted, as essential steps toward enhancing global eradication strategies.

Keywords: *Helicobacter pylori Eradication; Antibiotic Resistance; Amoxicillin; Peptic Ulcer Disease; H. pylori; High Dose Antibiotics; High Dose Amoxicillin; Dual Therapy; Triple Therapy*

1 INTRODUCTION

Helicobacter pylori (H. pylori) is a significant global health concern, infecting approximately half of the

world's population, with prevalence rates showing considerable variability across different regions[1]. The eradication of *H. pylori* is of paramount importance, given its established association with a range of serious gastrointestinal diseases, including peptic ulcers, gastritis, and gastric cancer. The bacterium's role in the progression of these diseases underscores the significant burden it places on healthcare systems, particularly in settings where diagnostic and treatment resources are limited[2].

However, the success of conventional treatment strategies is increasingly compromised by the global rise in antibiotic resistance. Resistance to commonly used antibiotics, such as clarithromycin and metronidazole, has reached alarming levels, significantly reducing the efficacy of standard eradication regimens [3]. This growing antibiotic resistance necessitates the exploration and development of novel therapeutic strategies.

1.1 Global prevalence

Prevalence rates vary significantly across different geographical regions, with higher rates observed in developing countries compared to industrialized nations. In developing regions, such as parts of Africa, Asia, and South America, prevalence rates can exceed 80%, while in industrialized nations, rates have generally declined due to improvements in living conditions and healthcare [4,5]. For instance, a meta-analysis covering 1748 studies across 111 countries estimated the global prevalence of *H. pylori* infection to be 43.9% (95% CI: 42.3-45.5%), with the highest prevalence observed in Africa region (52.7%) and the lowest in European region (39.6%). Prevalence tends to increase with age, with higher rates observed in adults when compared to children[6] .

These variations in prevalence are influenced by several factors, including socioeconomic status, sanitation standards, and cultural practices. Factors such as overcrowding, poor hygiene, and limited access to clean water contribute to higher rates of transmission in developing regions. Additionally, variations in healthcare infrastructure and access to diagnostic and treatment services also impact regional prevalence rates[1,7].

Costigan et al. (2024)[8] assessed the efficacy of high-dose amoxicillin therapy (HDAT) in treating H. pylori infections within an Irish cohort. The study reported disappointing eradication rates, leading the authors to advise against the use of HDAT in this population. These findings highlight the variability of HDAT's effectiveness across different populations, suggesting that geographical and genetic factors may influence treatment outcomes. As a result, it is important to further investigate HDAT’s potential in diverse demographic groups to better understand its role in combating H. pylori infection and to tailor treatment strategies accordingly. Despite efforts to reduce prevalence through public health interventions and improved sanitation, *H. pylori* infection remains a significant burden, particularly in regions with limited resources. Addressing this challenge requires comprehensive strategies that encompass prevention, diagnosis, and treatment to mitigate the associated health risks and improve overall outcomes[4].

1.2 CHALLENGES IN THE TREATMENT OF *H. pylori*

Eradicating *H. pylori* poses multiple challenges (Figure 1): antibiotic resistance, treatment compliance and adverse effects. The efficacy of commonly used antibiotics, such as clarithromycin and metronidazole, has significantly decreased due to rising resistance rates globally.



Figure 1: Challenges in the eradication of *H.Pylori.* Adverse drug reactions (ADRs), treatment non-compliance, and escalating antibiotic resistance represent significant obstacles in the eradication of *H. pylori*. These factors diminish therapeutic efficacy, impair patient adherence, and lead to higher treatment failure rates, thereby complicating the global eradication of the infection.

Treatment compliance is a significant hurdle in the management and eradication of *Helicobacter pylori* (*H. pylori*) infection. Compliance issues often arise due to the complexity and side effects of treatment regimens, which impact the overall success of eradication efforts. *H. pylori* treatment typically involves a combination therapy that includes two or three antibiotics plus a proton pump inhibitor, and is administered several times a day over a period of 7 - 14 days. The complexity and duration of these regimens can lead to confusion, forgetfulness, or deliberate nonadherence among patients[3]. The side effects associated with common eradication therapies can also deter patients from completing their treatment courses. These side effects often include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain, which can significantly decrease quality of life during treatment[2]. Factors such as the cost of medication, access to healthcare services, and patient education also play critical roles in treatment compliance. Patients from lower socioeconomic backgrounds or those with limited access to healthcare resources are more likely to experience challenges in adhering to treatment protocols[9].

Adverse reactions associated with current therapies can also discourage adherence to treatment protocols. These often include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain, which can significantly decrease quality of life during treatment[2].

1.3 THE ROLE OF *H. pylori* INFECTIONS IN CANCER

H. pylori infection is widely recognized as a major risk factor for several gastrointestinal cancers, particularly gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. The mechanisms by which *H. pylori* contributes to carcinogenesis are complex and multifactorial, involving both direct and indirect pathways that promote cancer development[10].

1.3.1 Molecular pathways and carcinogenesis

H. pylori directly interacts with the gastric mucosa, causing chronic inflammation and damage that can lead to cancer. Infection leads to the production of cytokines and other inflammatory mediators, which induce mutations, promote cellular proliferation, and inhibit apoptosis[11]. Moreover, certain virulent strains of *H. pylori* express the CagA protein, which is injected into gastric epithelial cells via a type IV secretion system. Once inside cells, CagA disrupts normal cell signaling and control mechanisms, further increasing the risk of cancer[12].

1.3.2 Epidemiological evidence

Epidemiological studies have consistently shown a strong association between *H. pylori* infection and the development of gastric cancer. The International Agency for Research on Cancer (IARC) classifies *H. pylori* as a class I carcinogen for gastric cancer. *H. pylori* infection is estimated to be responsible for approximately 89% of all noncardia gastric adenocarcinomas worldwide[13].

1.3.3 Preventive measures and screening

Given the significant role of *H. pylori* in gastric cancer, eradication of the infection is considered a crucial strategy for cancer prevention. Several studies have demonstrated that eradication therapy significantly reduces the incidence of gastric cancer in infected individuals, particularly among those without pre-existing severe gastric lesions[14]. Therefore, screening and treatment programs for *H. pylori* could serve as effective preventive measures against gastric cancer, especially in high-risk populations.

1.4 HIGH-DOSE AMOXICILLIN IN *H. pylori* ERADICATION

High-dose amoxicillin may overcome some resistance mechanisms by exceeding the minimum inhibitory concentrations required to suppress resistant strains. This section reviews the current literature on the pharmacodynamics of amoxicillin, its safety profile at higher doses, and preliminary clinical outcomes suggesting enhanced eradication rates.

1.4.1 Rationale for high dose amoxicillin use

Amoxicillin, a beta-lactam antibiotic, has been a cornerstone in the treatment of *H. pylori* because of its ability to inhibit cell wall synthesis. The rationale behind using high doses of amoxicillin involves overwhelming the bacterial defense mechanisms that typically contribute to resistance. Importantly, the effectiveness of amoxicillin is less influenced by the pH of the stomach than other antibiotics used in *H. pylori* eradication, such as clarithromycin and metronidazole[15].

High-dose amoxicillin is proposed as an alternative to potentially overcome bacterial resistance mechanisms. By achieving higher intragastric concentrations, it is hypothesized that high doses can exceed the minimum inhibitory concentrations (MICs) necessary to inhibit or kill resistant bacterial strains[16]. High-dose amoxicillin has the potential to maintain plasma and tissue concentrations that are effective against *H. pylori* for a longer period without causing significant toxicity. The relatively safe profile of amoxicillin allows its use at relatively high doses, which may optimize its bactericidal activity against *H. pylori*. Studies have demonstrated that dosing intervals and the maintenance of optimal drug levels are crucial for effectively eradicating infections, suggesting that higher doses could increase eradication rates by sustaining therapeutic

levels over the dosing interval[3].

1.4.2 Clinical evidence supporting high dose therapy

Recent studies have explored the impact of increasing the dosage of amoxicillin on eradication rates. A systematic review by Li *et al*. (2024)[17] analyzed several trials where amoxicillin was administered at doses ranging from 1.5 g to 3 g twice daily. The review revealed that higher doses were associated with improved eradication rates, especially in regions with high levels of resistance to clarithromycin and metronidazole. For example, a randomized controlled trial by Liou *et al*. (2016)[18] compared the standard dose (1 g twice daily) with a high dose (2 g twice daily) of amoxicillin in a triple therapy regimen, demonstrating that the eradication rate increased from 78% to 85%.

1.4.3 Pharmacokinetics and safety of high dose amoxicillin

Amoxicillin is generally well-tolerated, and even at higher doses, it maintains a favorable safety profile. The PK profile of amoxicillin is characterized by rapid absorption, with peak plasma concentrations typically reached within one to two hours postadministration. The drug has a relatively short half-life of approximately 1-1.5 hours in healthy individuals, which necessitates frequent dosing to maintain effective concentrations in the blood. Pharmacokinetic studies indicate that amoxicillin's half-life does not substantially change even with increased doses, ensuring steady-state levels conducive to bacterial eradication without significant toxicity. Increasing the dosage can increase the peak concentration and, potentially, the duration of effective concentration levels above the minimum inhibitory concentration (MIC) necessary to inhibit or kill *H. pylori* bacteria.

High doses of amoxicillin achieve relatively high plasma and gastric mucosal concentrations, which are crucial in eradicating gastric pathogens. The linear pharmacokinetics of amoxicillin indicate that its plasma concentrations increase proportionally with higher doses, thus potentially improving therapeutic outcomes in infections where high bacterial loads or resistant bacterial strains are present[19].

Pharmacodynamically, amoxicillin is a time-dependent antibiotic, meaning that its efficacy is primarily determined by the time at which its concentration remains above the MIC of the target organism. For *H. pylori*, the key PD parameter is the percentage of the dosing interval during which the drug concentration exceeds the MIC (T>MIC). High-dose regimens aim to maximize T>MIC, thus increasing bacterial killing rates. Studies suggest that for beta-lactam antibiotics such as amoxicillin, maintaining drug concentrations at four to five times the MIC could be necessary for optimal eradication of resistant bacterial strains[20]. Side effects, such as gastrointestinal disturbances and hypersensitivity reactions, do not significantly increase with increasing doses of amoxicillin[21].

The PK/PD relationship can vary significantly among individuals due to differences in drug absorption, metabolism, and excretion. Factors such as gastric pH, the gastric emptying rate, and the presence of food can affect the absorption of orally administered amoxicillin. Additionally, renal function plays a critical role in the excretion of amoxicillin; hence, patients with renal impairment may have higher and more prolonged plasma concentrations of the drug, potentially increasing efficacy but also the risk of toxicity[22].

1.4.4 Addressing antibiotic resistance

One of the primary benefits of high-dose amoxicillin therapy is its potential to overcome resistance. By

achieving higher gastric tissue concentrations, high-dose amoxicillin may exert sufficient pressure to overcome resistance mechanisms, such as penicillin-binding protein alterations in *H. pylori*[23,24]. Moreover, high-dose regimens could reduce the selective pressure for resistance development, as they may shorten the duration of therapy needed to achieve eradication.

1.4.5 Limitations and considerations

Despite these advantages, there are limitations to consider with high-dose amoxicillin therapy. The increased cost, the potential for noncompliance due to the larger volume of medication, and the lack of long-term studies on the outcomes of such regimens must be considered[25]. Furthermore, the efficacy and safety of high-dose amoxicillin in specific populations, such as children and patients with renal impairment, require additional study.

1.5 DRUG RESISTANCE AND THE FUTURE OF H. pylori THERAPY

The development of antibiotic resistance in *H. pylori* is a major public health concern that drives the need for innovative treatment strategies. Current research focuses on the development of new antibiotics, alternative therapies such as probiotics, vaccines, and phage therapy. Furthermore, optimizing existing treatment regimens and developing personalized medicine approaches on the basis of genetic susceptibility and bacterial strain-specific factors are critical[26].

1.5.1 Current state of drug resistance

The challenge of antibiotic resistance persists in the eradication of *H. pylori*, with resistance to essential antibiotics such as clarithromycin, metronidazole, and levofloxacin, which are commonly employed in treatment protocols, increasing worldwide. Global surveillance studies report resistance rates for these antibiotics to be as high as 15-50% in various regions, significantly reducing the success rates of conventional triple therapies[27,28]. The World Health Organization (WHO) has recognized *H. pylori* as a priority pathogen for which new antibiotics are urgently needed. This resistance limits the effectiveness of commonly used therapies and necessitates a deeper understanding of their mechanisms and impacts.

1.5.2 Mechanisms of Resistance

Clarithromycin resistance: One of the most critical issues in *H. pylori* treatment, clarithromycin resistance, typically arises from point mutations in the 23S rRNA gene of the bacterium. These mutations prevent clarithromycin from binding to the ribosome, thereby inhibiting its bacteriostatic effect. Studies have shown that such mutations can reduce the efficacy of treatment regimens involving clarithromycin from over 80% to below 50% in some populations[16].
Metronidazole resistance: Resistance to metronidazole in *H. pylori* is primarily due to the increased activity of nitroreductases that reduce the nitro group of metronidazole, leading to drug inactivation. Genetic modifications such as mutations in the rdxA gene (an oxygen-insensitive NADPH nitroreductase) play a significant role in this resistance mechanism[29-31].
Multi-drug resistance: *H. pylorus has* also shown capabilities for multidrug resistance, particularly through efflux pump systems that expel multiple antibiotics from the cell, reducing their intracellular concentrations and effectiveness. The overexpression of certain efflux pump genes in *H. pylori* strains has been linked to reduced susceptibility to tetracycline, levofloxacin, and other antibiotics[32].

Impact of resistance: The increasing prevalence of antibiotic-resistant *H. pylori* strains has significant clinical implications. This leads to lower eradication rates and increased treatment failures and necessitates the use of alternative, often more complex and costly, treatment regimens. Additionally, the evolution of resistance can lead to longer infection durations, which are associated with higher risks of developing gastritis, peptic ulcers, and gastric cancer[33–35].

1.5.3 Emerging therapies to combat resistance

As antibiotic resistance in *Helicobacter pylori* continues to increase, researchers are exploring several innovative strategies to enhance eradication efforts. These approaches range from the development of new pharmaceuticals to alternative nonantibiotic therapies, each aimed at overcoming current treatment challenges.

The development of new antibiotics that *H. pylori* has not yet encountered is a critical area of research. For example, rifabutin-based therapies have shown promise in preliminary trials as effective second-line treatments[36]. In addition, researchers are designing innovative treatment regimens that combine multiple antibiotics, which *H. pylori* has not yet resisted, with agents such as efflux pump inhibitors that can block resistance mechanisms[37].

Moreover, interest in non-antibiotic therapies, such as vaccines, probiotics, and phage therapy, is increasing. A vaccine against *H. pylori* is particularly desirable as it could eradicate the infection preemptively [38]. Probiotics have also shown some efficacy in improving eradication rates and reducing side effects when used alongside antibiotic therapy[39-41].

Furthermore, tailoring antibiotic therapy on the basis of genetic testing of *H. pylori* strains obtained from biopsy samples is becoming increasingly feasible. This approach allows for the determination of the most effective antibiotics against a specific infection, enhancing treatment precision and effectiveness[42].

1.5.4 The role of national and global health policies

Addressing *Helicobacter pylori* resistance effectively requires coordinated efforts at both the national and global levels. Health policies should focus on promoting several key strategies. First, implementing surveillance programs that regularly monitor antibiotic resistance patterns is crucial; these data can inform and update clinical guidelines appropriately[43]. Additionally, increasing education and awareness about *H. pylori* infection, its potential complications, and the importance of adhering to prescribed therapies is vital for managing the public health impact of the bacterium[4].Finally, there should be a strong emphasis on research and development. This includes encouraging and providing funding for the exploration of new therapies and diagnostic tools, which are essential in the fight against this persistent and evolving pathogen[24]. Together, these measures can result in a robust response to the growing challenge of antibiotic resistance in *H. pylori* treatment.

1.5.5 Future research perspectives

Future studies should focus on large-scale clinical trials to validate the efficacy and safety of high-dose amoxicillin therapy. Additionally, research into the mechanisms of resistance, particularly how high-dose therapy affects resistance development, is essential. Investigating the role of host and bacterial genomics may also provide insights into more effective and tailored therapies[44].

As the battle against *Helicobacter pylori* continues, particularly in the face of increasing antibiotic resistance, focusing on innovative research strategies becomes imperative.

1.5.6 Advanced diagnostic technologies:

Continued advances in diagnostic methodologies are essential to accurately identify *H. pylori* infections and swiftly detect antibiotic resistance[45]. Modern techniques such as whole-genome sequencing and polymerase chain reaction (PCR)-based methods allow for rapid and precise detection of resistance-associated mutations. These tools can guide the selection of appropriate antibiotics, improving treatment outcomes. Molecular diagnostics such as CRISPR-based diagnostics could provide faster, more accurate insights into genetic mutations associated with antibiotic resistance[46]. Furthermore, the development of rapid, reliable point-of-care testing for *H. pylori* and its resistance profiles could improve access to appropriate therapy, particularly in low-resource settings.

1.5.7 Novel therapeutic agents:

Given that antibiotic resistance diminishes the efficacy of existing treatments, there is a critical need for novel therapeutic agents. The discovery and development of new antibiotics that *H. pylori* has not yet encountered could help circumvent existing resistance mechanisms[44]. Additionally, bacteriophage therapy, which specifically targets *H. pylori*, could open new avenues for treatment, particularly as an adjunct to antibiotic therapy[47].

1.5.8 Vaccine development:

The development of a preventive vaccine for *H. pylori* remains a high priority. Protein subunit vaccines, which identify immunogenic proteins in *H. pylori* that can be used in subunit vaccines, could provide a path forward in vaccine development[47].

1.5.9 Understanding Host-Microbe Interactions:

A deeper understanding of the interaction between *H. pylori* and the host immune system could reveal new therapeutic targets. Studying how *H. pylori* evades the immune system might lead to novel approaches to improve host defense mechanisms[11]. Additionally, investigating the role of the gut microbiome in *H. pylori* infection and persistence could provide insights into probiotic treatments or microbiome-modulating strategies[48,49].

1.5.10 Optimization of treatment regimens:

Optimizing current treatment strategies to improve efficacy and reduce side effects is crucial. Tailoring treatment on the basis of individual genetic markers of susceptibility and resistance could improve eradication rates[23,50]. Furthermore, exploring combinations of existing drugs with new agents, or with different modalities such as probiotics, could improve treatment outcomes[37].

1.5.11 Longitudinal studies and surveillance:

Long-term studies and continued surveillance are necessary to monitor trends in antibiotic resistance and treatment outcomes. Strengthening and expanding global networks to monitor *H. pylori* resistance patterns

would help in updating treatment guidelines promptly.

1.5.12 Socioeconomic impact assessments:

Research into the socioeconomic impacts of *H. pylori* infection and its treatment can aid in policy formulation. Evaluating the cost-effectiveness of new treatments and diagnostic methods can support healthcare policy decisions[51,52].

1.6 CONCLUSION

High-dose amoxicillin has emerged as a promising strategy for combating *H. pylori* infections, especially with increasing antibiotic resistance. Nevertheless, extensive research is imperative to grasp its full potential and establish guidelines that enhance treatment efficacy while mitigating potential risks. This necessitates comprehensive investigations into its effectiveness across diverse patient cohorts and thorough assessments of its long-term safety profile. Additionally, refining treatment protocols on the basis of individual patient characteristics, such as antibiotic susceptibility and genetic factors, is crucial for tailoring therapies to maximize efficacy. Thus, while high-dose amoxicillin shows considerable promise, further research and evidence-based guidelines are essential to ensure its optimal utilization, thereby maximizing treatment success and minimizing adverse effects.

REFERENCES

1 **Hooi JKY**, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology* 2017; **153**: 420-429 [PMID: 28456631 DOI: 10.1053/j.gastro.2017.04.022]

2 **Chey WD**, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol* 2017; **112**: 212-239 [PMID: 28071659 DOI: 10.1038/ajg.2016.563]

3 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

4 **Li Y**, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2023; **8**: 553-564 [PMID: 37086739 DOI: 10.1016/S2468-1253(23)00070-5]

5 **FitzGerald R**, Smith SM. An Overview of Helicobacter pylori Infection. *Methods Mol Biol* 2021; **2283**: 1-14 [PMID: 33765303 DOI: 10.1007/978-1-0716-1302-3_1]

6 **Chen YC**, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, Wu YX, Hsiao JL, Chen MJ, Lin KP, Wu CY, Lin JT, O'Morain C, Megraud F, Lee WC, El-Omar EM, Wu MS, Liou JM. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. *Gastroenterology* 2024; **166**: 605-619 [PMID: 38176660 DOI: 10.1053/j.gastro.2023.12.022]

7 **Sjomina O**, Pavlova J, Niv Y, Leja M. Epidemiology of Helicobacter pylori infection. *Helicobacter* 2018; **23 Suppl 1**: e12514 [PMID: 30203587 DOI: 10.1111/hel.12514]

8 **Costigan C**, O'Sullivan AM, O'Connell J, Sengupta S, Butler T, Molloy S, O'Hara FJ, Ryan B, Breslin N, O'Donnell S, O'Connor A, Smith S, McNamara D. Helicobacter pylori: High dose amoxicillin does not improve primary or secondary eradication rates in an Irish cohort. *World J Clin Cases* 2024; **12**: 2773-2779 [PMID: 38899284 DOI: 10.12998/wjcc.v12.i16.2773]

9 **Graham DY**, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. *Clin Gastroenterol Hepatol* 2014; **12**: 177-86.e3; Discussion e12-3 [PMID: 23751282 DOI: 10.1016/j.cgh.2013.05.028]

10 **Reyes VE**. Helicobacter pylori and Its Role in Gastric Cancer. *Microorganisms* 2023; **11** [PMID: 37317287 DOI: 10.3390/microorganisms11051312]

11 **Backert S**, Yamaoka Y. Helicobacter pylori Research: From Bench to Bedside. Springer Available from: https://books.google.com/books/about/Helicobacter_pylori_Research.html?hl=&id=mUm-ugEACAAJ

12 **Polk DB**, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. *Nat Rev Cancer* 2010; **10**: 403-414 [PMID: 20495574 DOI: 10.1038/nrc2857]

13 **Kumar S**, Mantero A, Delgado C, Dominguez B, Nuchovich N, Goldberg DS. Eastern European and Asian-born populations are prone to gastric cancer: an epidemiologic analysis of foreign-born populations and gastric cancer. *Ann Gastroenterol* 2021; **34**: 669-674 [PMID: 34475737 DOI: 10.20524/aog.2021.0640]

14 **Ford AC**, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. *Gut* 2020; **69**: 2113-2121 [PMID: 32205420 DOI: 10.1136/gutjnl-2020-320839]

15 **Yang JC**, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. *Clin Gastroenterol Hepatol* 2015; **13**: 895-905.e5 [PMID: 25460556 DOI: 10.1016/j.cgh.2014.10.036]

16 **Kim JL**, Cho SJ, Chung SJ, Lee A, Choi J, Chung H, Kim SG. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial. *Clin Transl Gastroenterol* 2020; **11**: e00194 [PMID: 33094958 DOI: 10.14309/ctg.0000000000000194]

17 **Li J**, Shi H, Zhou F, Xie L, Lin R. The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China: A Systemic Review and Network Meta-Analysis. *J Clin Gastroenterol* 2024; **58**: 12-23 [PMID: 38084866 DOI: 10.1097/MCG.0000000000001902]

18 **Liou JM**, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ, Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital

populations: a randomised trial. *Gut* 2016; **65**: 1784-1792 [PMID: 26338825 DOI: 10.1136/gutjnl-2015-310142]

19 **Vinks AA**, Derendorf H, Mouton JW. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. Springer Science & Business Media Available from: https://play.google.com/store/books/details?id=i_G8BAAAQBAJ

20 **Rotschafer JC**, Andes DR, Rodvold KA. Antibiotic Pharmacodynamics. Humana Available from:https://books.google.com/books/about/Antibiotic_Pharmacodynamics.html?hl=&id=ixcOswEACAAJ

21 **von Muhlenbrock C**, Cordova A, Nuñez P, Pacheco N, Herrera K, Quera R. Eradication rate and adherence with high-dose amoxicillin and proton pump inhibitor as first-line treatment for Helicobacter pylori infection: Experience from University Hospital in Chile. *Helicobacter* 2024; **29**: e13052 [PMID: 38332683 DOI: 10.1111/hel.13052]

22 **Qasim A**, O'Morain CA, O'Connor HJ. Helicobacter pylori eradication: role of individual therapy constituents and therapy duration. *Fundam Clin Pharmacol* 2009; **23**: 43-52 [PMID: 19207543 DOI: 10.1111/j.1472-8206.2008.00635.x]

23 **Mascellino MT**, Malfertheiner P, Pontone S, Vega AE. Helicobacter pylori infection: pathogenesis, antibiotic resistance, advances and therapy, new treatment strategies. Frontiers Media SA Available from: https://books.google.com/books/about/Helicobacter_pylori_infection_pathogenes.html?hl=&id=IVqmEAAAQBAJ

24 **Hong TC**, El-Omar EM, Kuo YT, Wu JY, Chen MJ, Chen CC, Fang YJ, Leow AHR, Lu H, Lin JT, Tu YK, Yamaoka Y, Wu MS, Liou JM; Asian Pacific Alliance on Helicobacter and Microbiota. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2024; **9**: 56-67 [PMID: 37972625 DOI: 10.1016/S2468-1253(23)00281-9]

25 **Hu JL**, Yang J, Zhou YB, Li P, Han R, Fang DC. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. *Saudi J Gastroenterol* 2017; **23**: 275-280 [PMID: 28937021 DOI: 10.4103/sjg.SJG_91_17]

26 **Li S**, Zhao W, Xia L, Kong L, Yang L. How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans? *Infect Drug Resist* 2023; **16**: 3787-3805 [PMID: 37342435 DOI: 10.2147/IDR.S412361]

27 **Khoshnood S**, Pakzad R, Kaviar VH, Hashemian M, Karamollahi S, Sadeghifard N, Heidarizadeh H, Moradi M, Maleki A, Heidary M, Abdi M. Global Estimate of Clarithromycin Resistance in Clinical Isolates of Helicobacter pylori: a Systematic Review and Meta-Analysis. *Clin Lab* 2023; **69** [PMID: 37436391 DOI: 10.7754/Clin.Lab.2022.221032]

28 **Schubert JP**, Ingram PR, Warner MS, Rayner CK, Roberts-Thomson IC, Costello SP, Bryant RV. Refractory Helicobacter pylori infection in Australia: updated multicentre antimicrobial resistance. *Intern Med J* 2023; **53**: 1972-1978 [PMID: 37705320 DOI: 10.1111/imj.16226]

29 **Gong Y**, Zhai K, Sun L, He L, Wang H, Guo Y, Zhang J. RdxA Diversity and Mutations Associated with

Metronidazole Resistance of Helicobacter pylori. *Microbiol Spectr* 2023; **11**: e0390322 [PMID: 36943041 DOI: 10.1128/spectrum.03903-22]

30 **Losurdo G**, Pricci M, De Bellis M, Celiberto F, Russo F, Riezzo G, D'attoma B, Iannone A, Rendina M, Ierardi E, Di Leo A. Effect of metronidazole resistance on Helicobacter pylori eradication regimens. *J Dig Dis* 2022; **23**: 561-567 [PMID: 36321440 DOI: 10.1111/1751-2980.13142]

31 **Nemr N**, Kishk RM, Salem A, Abdalla MO, Abd El-Fadeal NM, Soliman NM. Genotypic detection of metronidazole and clarithromycin resistance in dyspeptic patients with helicobacter pylori. *Environ Sci Pollut Res Int* 2022; **29**: 41467-41474 [PMID: 35088259 DOI: 10.1007/s11356-021-18198-4]

32 **Lara Icaza JD**, Tapia RL, Triana CTC, Ramírez LCR. Refractoriness to anti-Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil-Ecuador. *Helicobacter* 2024; **29**: e13060 [PMID: 38581134 DOI: 10.1111/hel.13060]

33 **Wang H**, Kong QZ, Li YY, Yang XY, Zuo XL. High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis. *J Dig Dis* 2024; **25**: 163-175 [PMID: 38577962 DOI: 10.1111/1751-2980.13263]

34 **Shao Y**, Lin Y, Fang Z, Yan J, Zheng T, Ye G. Analysis of Helicobacter pylori resistance in patients with different gastric diseases. *Sci Rep* 2024; **14**: 4912 [PMID: 38418852 DOI: 10.1038/s41598-024-55589-2]

35 **Dutta S**, Jain S, Das K, Verma P, Som A, Das R. Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review. *Helicobacter* 2024; **29**: e13057 [PMID: 38415810 DOI: 10.1111/hel.13057]

36 **Li X**, Liu Y, Wang M, Gao L, Liu J, Zhang H, Wu M, Chen H, Lou J, Wang J, Chen J, Geng G, Ma Z, Ding Y. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials. *Lancet Infect Dis* 2024; **24**: 650-664 [PMID: 38359854 DOI: 10.1016/S1473-3099(24)00003-3]

37 **Godavarthy PK**, Puli C. From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment. *Cureus* 2023; **15**: e36041 [PMID: 36919111 DOI: 10.7759/cureus.36041]

38 **Lin Y**, Shao Y, Yan J, Ye G. Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice. *J Clin Lab Anal* 2023; **37**: e24885 [PMID: 37088871 DOI: 10.1002/jcla.24885]

39 **Al-Fakhrany OM**, Elekhnawy E. Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents. *Arch Microbiol* 2023; **205**: 301 [PMID: 37550555 DOI: 10.1007/s00203-023-03639-0]

40 **Baryshnikova NV**, Ilina AS, Ermolenko EI, Uspenskiy YP, Suvorov AN. Probiotics and autoprobiotics for treatment of Helicobacter pylori infection. *World J Clin Cases* 2023; **11**: 4740-4751 [PMID: 37583996 DOI: 10.12998/wjcc.v11.i20.4740]

41 **McFarland LV**, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: Multi-strain

probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. *United European Gastroenterol J* 2016; **4**: 546-561 [PMID: 27536365 DOI: 10.1177/2050640615617358]

42 **Kouitcheu Mabeku LB**, Eyoum Bille B, Tepap Zemnou C, Tali Nguefack LD, Leundji H. Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. *BMC Infect Dis* 2019; **19**: 880 [PMID: 31640588 DOI: 10.1186/s12879-019-4536-8]

43 **Sadeghi A**, Nouri F, Taherifard E, Shahlaee MA, Dehdari Ebrahimi N. Estimates of global and regional prevalence of Helicobacter pylori infection among individuals with obesity: a systematic review and meta-analysis. *Infection* 2024; **52**: 1223-1234 [PMID: 38594573 DOI: 10.1007/s15010-024-02244-7]

44 **Shatila M**, Thomas AS. Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection. *J Clin Med* 2022; **11** [PMID: 36079015 DOI: 10.3390/jcm11175086]

45 **Kato M**, Ono S, Kawada K, Dohi O, Kitamura S, Koike T, Hori S, Kanzaki H, Murao T, Yagi N, Sasaki F, Hashiguchi K, Oka S, Katada K, Shimoda R, Mizukami K, Suehiro M, Takeuchi T, Katsuki S, Tsuda M, Naito Y, Kawano T, Haruma K, Mori K, Ishikawa H. Diagnostic performance of linked color imaging for gastric cancer by Helicobacter pylori infection status: A subanalysis of the large-scale, multicenter randomized controlled trial LCI-FIND. *Helicobacter* 2024; **29**: e13080 [PMID: 38671594 DOI: 10.1111/hel.13080]

46 **Qiu E**, Jin S, Xiao Z, Chen Q, Wang Q, Liu H, Xie C, Chen C, Li Z, Han S. CRISPR-based detection of Helicobacter pylori in stool samples. *Helicobacter* 2021; **26**: e12828 [PMID: 34117655 DOI: 10.1111/hel.12828]

47 **Sutton P**, Boag JM. Status of vaccine research and development for Helicobacter pylori. *Vaccine* 2019; **37**: 7295-7299 [PMID: 29627231 DOI: 10.1016/j.vaccine.2018.01.001]

48 **Sutton P**, Mitchell HM. Helicobacter Pylori in the 21st Century. CABI Available from: https://books.google.com/books/about/Helicobacter_Pylori_in_the_21st_Century.html?hl=&id=RJuS0yre0W8C

49 **Mégraud F**, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. *Clin Microbiol Rev* 2007; **20**: 280-322 [PMID: 17428887 DOI: 10.1128/CMR.00033-06]

50 **Liou JM**, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, Tseng PH, Chang L, Chang WH, Wang HP, Shun CT, Wu JY, Lee YC, Lin JT, Wu MS; Taiwan Helicobacter Consortium. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. *J Antimicrob Chemother* 2013; **68**: 450-456 [PMID: 23099849 DOI: 10.1093/jac/dks407]

51 **Sarmasti M**, Khoshbaten M, Khalili F, Yousefi M. Cost-Effectiveness of Screening Helicobacter pylori for Gastric Cancer Prevention: a Systematic Review. *J Gastrointest Cancer* 2022; **53**: 1093-1103 [PMID: 34694594 DOI: 10.1007/s12029-021-00726-7]

52 **Qin Y**, Tong X, Fan J, Liu Z, Zhao R, Zhang T, Suo C, Chen X, Zhao G. Global Burden and Trends in Incidence, Mortality, and Disability of Stomach Cancer From 1990 to 2017. *Clin Transl Gastroenterol* 2021;

12: e00406 [PMID: 34608884 DOI: 10.14309/ctg.0000000000000406]

Footnotes

Conflict-of-interest statement: Authors have nothing to disclose.